Literature DB >> 17560866

Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes.

Luca Testa1, Giuseppe Biondi Zoccai, Italo Porto, Graziana Trotta, Pierfrancesco Agostoni, Felicita Andreotti, Filippo Crea.   

Abstract

After acute coronary syndromes, the beneficial effect of aspirin plus clopidogrel (A+C) or aspirin plus dose-adjusted warfarin (A+W) compared with aspirin alone is well established. However, these regimens were never compared. To compare the risk-benefit profile of A+C versus A+W after acute coronary syndromes, major medical databases for randomized controlled trials comparing 1 of these combined approaches versus aspirin alone after an acute coronary syndrome (updated June 2006) were searched. Evaluated end points were major adverse events [MAEs: all-cause death, acute myocardial infarction [AMI], thromboembolic stroke, major bleeds, and overall risk of stroke [hemorrhagic or ischemic]). Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated for (1) A+W versus aspirin alone, (2) A+C versus aspirin alone, and (3) A+W versus A+C using adjusted indirect meta-analysis. Thirteen studies were included, totaling 69,741 patients. Ten compared A+W versus aspirin alone and 3 compared A+C versus aspirin alone. Each combined approach yielded a significantly lower risk of MAEs, albeit an increased risk of major bleeds, compared with aspirin alone. No significant difference was found for A+W versus A+C for risk of overall MAEs, death, or AMI. However, A+W versus A+C was associated with a significantly lower risk of thromboembolic stroke (OR 0.53, 95% CI 0.31 to 0.88, number needed to treat 60) and all types of stroke (OR 0.58, 95% CI 0.35 to 0.94, p=0.038), but also with increased risk of major bleeds (OR 1.9, 95% CI 1.2 to 2.8, number needed to harm 300). In conclusion, after an acute coronary syndrome, A+W and A+C are comparable in the prevention of MAEs, death, and AMI compared with aspirin alone. Allocating 100 patients to A+W (at international normalized ratio 2 to 3) with respect to A+C could prevent 17 thromboembolic strokes while causing 3 major bleeds.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17560866     DOI: 10.1016/j.amjcard.2007.01.052

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  9 in total

Review 1.  The myth of 'stable' coronary artery disease.

Authors:  Keith A A Fox; Marco Metra; João Morais; Dan Atar
Journal:  Nat Rev Cardiol       Date:  2019-07-29       Impact factor: 32.419

Review 2.  Anticoagulation in Patients with Ischaemic Heart Disease and Peripheral Arterial Disease: Clinical Implications of COMPASS Study.

Authors:  Josep Gradolí; Verónica Vidal; Adrian Jb Brady; Lorenzo Facila
Journal:  Eur Cardiol       Date:  2018-12

3.  Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial.

Authors:  Renato D Lopes; Laine E Elliott; Harvey D White; Judith S Hochman; Frans Van de Werf; Diego Ardissino; Torsten T Nielsen; W Douglas Weaver; Petr Widimsky; Paul W Armstrong; Christopher B Granger
Journal:  Eur Heart J       Date:  2009-06-06       Impact factor: 29.983

4.  Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention After Acute Coronary Syndromes: A Systematic Review and Meta-analysis.

Authors:  Mauro Chiarito; Davide Cao; Francesco Cannata; Cosmo Godino; Corrado Lodigiani; Giuseppe Ferrante; Renato D Lopes; John H Alexander; Bernhard Reimers; Gianluigi Condorelli; Giulio G Stefanini
Journal:  JAMA Cardiol       Date:  2018-03-01       Impact factor: 14.676

Review 5.  Combining oral anticoagulation and antiplatelet therapies: appropriate patient selection.

Authors:  Jeremy W Vandiver; K Diane Beavers
Journal:  J Thromb Thrombolysis       Date:  2018-04       Impact factor: 2.300

Review 6.  Rivaroxaban in patients with a recent acute coronary syndrome event: integration of trial findings into clinical practice.

Authors:  Ganesh Nallur Shivu; Nick Ossei-Gerning
Journal:  Vasc Health Risk Manag       Date:  2014-05-12

7.  Antithrombotic therapy in patients with acute coronary syndrome in the intermountain heart collaborative study.

Authors:  Stacey Knight; Winslow Klaskala; Scott C Woller; Benjamin D Horne; T Jared Bunch; Viet T Le; Roger M Mills; Joseph B Muhlestein
Journal:  Cardiol Res Pract       Date:  2015-01-08       Impact factor: 1.866

Review 8.  The "dual-pathway" strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial.

Authors:  Marc Cohen; Deepa Iyer
Journal:  Cardiovasc Ther       Date:  2014-10       Impact factor: 3.023

Review 9.  Anticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decade.

Authors:  Dan Atar; Christoph Bode; André Stuerzenbecher; Freek W A Verheugt
Journal:  Fundam Clin Pharmacol       Date:  2014-03-10       Impact factor: 2.748

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.